Morgan Stanley’s Humacyte Inc Warrant HUMAW Stock Holding History

Morgan Stanley’s Portfolio HUMAW Stock Details HUMAW Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	–	Sell	-600	Closed	-$1K	–	7778
2022 Q2	$1K	Sell	600 -150	-20%	-$230	﹤0.01%	7682
2022 Q1	$1K	Hold	750	–	–	﹤0.01%	7844
2021 Q4	$2K	Hold	750	–	–	﹤0.01%	7794
2021 Q3	$2K	Buy	+750	New	+$2.2K	﹤0.01%	7664
2021 Q2	–	Sell	-586	Closed	-$2K	–	7765
2021 Q1	$2K	Buy	+586	New	+$1.39K	﹤0.01%	7270

Other funds holding HUMAW

CVI Holdings Wilmington, Delaware $116M AUM 5.68% 1-Year Est. Return

LPL Financial San Diego, California $377B AUM 19.32% 1-Year Est. Return

LMR Partners London, United Kingdom $45.4B AUM 60.68% 1-Year Est. Return

RPO LLC Stamford, Connecticut $32.3M AUM 14.17% 1-Year Est. Return

Jane Street New York $777B AUM 61.18% 1-Year Est. Return

SCM

Sio Capital Management New York $697M AUM 79.73% 1-Year Est. Return

HRT Financial New York $40.1B AUM 58.22% 1-Year Est. Return

ETH

Exos TFP Holdings New York $162M AUM 16.08% 1-Year Est. Return

PSAMP

P. Schoenfeld Asset Management (PSAM) New York $184M AUM 97.09% 1-Year Est. Return

Verition Fund Management Greenwich, Connecticut $15.4B AUM 30.69% 1-Year Est. Return

Morgan Stanley's HUMAW Position: Q3 2022 in Review

Morgan Stanley sold out of Humacyte Inc Warrant (HUMAW) in Q3 2022, closing a stake of 600 shares — an estimated $1K sold.

Morgan Stanley first reported a position in HUMAW in Q1 2021 and held it in 5 quarters. The position peaked at $2K in Q4 2021. 10 funds tracked by Wall St. Rank hold HUMAW as of Q3 2022.

Morgan Stanley reported no remaining Humacyte Inc Warrant position as of Q3 2022 after selling out during the quarter.
Morgan Stanley sold 600 Humacyte Inc Warrant shares in Q3 2022, an estimated $1K.
Morgan Stanley first reported a position in Humacyte Inc Warrant in Q1 2021 and held it in 5 quarters.
Morgan Stanley's Humacyte Inc Warrant position peaked at $2K in Q4 2021.
10 funds tracked by Wall St. Rank held Humacyte Inc Warrant as of Q3 2022.

Based on Morgan Stanley's 13F filing for Q3 2022, filed 14 Nov 2022.